AbbVie Q3 2026 Results show $17.404B revenue, led by Skyrizi and Rinvoq, with higher 2026 EPS guidance and a 5.2% dividend increase.
The Merck Daejeon bioprocessing center opened on 29 October 2026 with a €300 million-plus investment, adding cell culture media, process liquids and sterile sampling capacity for Asia-Pacific biopharma manufacturers.
Sandoz 2026 sales reached USD 8,703 million in the first nine months, up 5% at constant currencies, with biosimilars up 19% and generics down 1%. The company narrowed full-year net-sales growth guidance to 5-6% and upgraded its core-EBITDA margin outlook to 23.0-23.5%.
Novartis Q3 2026 results show net sales of USD 14.5 billion (+4%) and core operating income up 11%. The company raised its full-year core operating income guidance despite a USD 1.9 billion del-desiran impairment.
IQVIA Q3 2026 Results show revenue of $4,428 million, adjusted diluted EPS of $3.34, $3.2 billion in R&D Solutions net new bookings and raised full-year 2026 guidance.
Johnson & Johnson will present more than 25 solid tumor abstracts at ESMO 2026, led by the first JNJ-6143 RIPTAC readout in prostate cancer, new RYBREVANT FASPRO head and neck data and ERLEADA PROTEUS findings.
Abbott Q3 2026 Results show net sales of $13.013 billion, up 14.5% reported and 7.0% comparable, with adjusted EPS of $1.42 and full-year EPS guidance tightened to $5.50 to $5.55.
Charles River, Labcorp and the FDA have signed a Research Collaboration Agreement to develop sensitive preclinical tools that quantify and rank the abuse potential of new drugs, including abuse-deterrent formulations.
Samsung Biologics Q3 2026 Results show revenue of KRW 1,490 billion and operating profit of KRW 640 billion. Plant 5 ramp-up and the Rockville site contributed, and the company raised its 2026 revenue growth guidance to 20%.
The Silence Therapeutics acquisition gives Merck KGaA, Darmstadt, Germany, the Phase 3-ready siRNA therapy Divesiran for polycythemia vera. The deal carries a $1.1 billion enterprise value and is expected to close in Q1 2027.
